Latest News

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

One thing we could say about the analysts on I-Tech AB ( STO:ITECH ) - they aren't optimistic, having just made a major...

Key Insights Significantly high institutional ownership implies CellaVision's stock price is sensitive to their trading...

By buying an index fund, investors can approximate the average market return. But many of us dare to dream of bigger...

Following the solid earnings report from Emova Group SA ( EPA:ALEMV ), the market responded by bidding up the stock...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

It's been a good week for Inwido AB (publ) ( STO:INWI ) shareholders, because the company has just released its latest...

Grand City Properties S.A. ( ETR:GYC ), is not the largest company out there, but it saw significant share price...

Key Insights The considerable ownership by private companies in Better Collective indicates that they collectively have...

LINK Mobility Group Holding ASA ( OB:LINK ) shares have had a horrible month, losing 26% after a relatively good period...

In the last year, many Euronext N.V. ( EPA:ENX ) insiders sold a substantial stake in the company which may have...

Eisen- und Hüttenwerke AG's ( FRA:EIS ) healthy profit numbers didn't contain any surprises for investors. However the...

With a median price-to-sales (or "P/S") ratio of close to 1x in the Electric Utilities industry in Germany, you could...

In late January 2026, Intellia Therapeutics reported that the FDA lifted the clinical hold on its MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) for patients with hereditary transthyretin amyloidosis with polyneuropathy, following protocol changes and enhanced liver safety monitoring. This decision allows Intellia to restart enrollment in a key late-stage program for a gene-editing therapy that aims to permanently inactivate the TTR gene, potentially reshaping treatment options...

If you are wondering whether Kerry Group at €77.00 is starting to look like value, you are not alone, especially given how far the share price has come over recent years. The stock has returned 2.9% over the last 7 days and 4.8% over the last 30 days, yet it is still showing a 1% gain year to date and a 20% decline over the past year, with 3 year and 5 year returns of 5.9% and 24.6% declines respectively. These moves have come as investors continue to reassess long term expectations for...

Block (XYZ) is back in focus after rolling out Bitcoin payments for Square merchants and launching a second generation Square Register, while also attracting fresh capital from ARK Invest and renewed analyst attention. See our latest analysis for Block. Those product launches and crypto ties are arriving after a tough stretch, with a 30 day share price return showing a 21.69% decline and a 1 year total shareholder return showing a 34.40% loss, which points to fading momentum despite a recent...

Earnings momentum and guidance behind the latest interest in Viavi Solutions Viavi Solutions (VIAV) has moved into focus after its recent earnings report, where management highlighted revenue contributions from data center and aerospace and defense customers, along with guidance calling for third quarter net revenue of US$386 million to US$400 million. See our latest analysis for Viavi Solutions. Those earnings and the guidance appear to have shifted sentiment quickly, with the share price at...

MannKind Corporation previously announced that the FDA approved an update to Afrezza’s Prescribing Information, revising starting mealtime doses for adults switching from injected or pump-delivered insulin based on recent modeling and clinical data. This label change is noteworthy because it offers clearer conversion guidance for clinicians, potentially making transitions to Afrezza more clinically manageable while highlighting its pulmonary safety considerations. With this labeling update...

While Infrea AB ( STO:INFREA ) might not have the largest market cap around , it saw a significant share price rise of...

If you are wondering whether Cleveland-Cliffs is priced attractively right now, this article walks you through what the current share price might be implying about the company. The stock recently closed at US$14.73, with returns of 7.0% over 7 days, 22.3% over 30 days, 8.3% year to date and 46.7% over 1 year. The 3 year and 5 year returns stand at 26.1% and 11.3% declines respectively. These moves sit against a broader backdrop where investors continue to reassess US steel and iron ore...

Biogen's high dose nusinersen (SPINRAZA) regimen for spinal muscular atrophy has published new clinical results in Nature Medicine and is currently under FDA review. The FDA has granted Breakthrough Therapy Designation to litifilimab for cutaneous lupus erythematosus, highlighting another late stage program for the company. For investors watching Biogen (NasdaqGS:BIIB), these two updates come at a time when the stock is trading around $201.18. The share price reflects a mixed track record,...

China Shenhua Energy (SEHK:1088) has guided for 2025 profit attributable to equity holders of RMB 50.8b to RMB 55.8b. This implies a year-on-year decline as softer coal demand and pricing pressure weigh on results. See our latest analysis for China Shenhua Energy. The earnings guidance has arrived after a strong period for investors, with China Shenhua Energy’s 1-year total shareholder return of 51.57% contrasting with only modest recent share price moves. These include a 30-day share price...

If you are looking at United States Antimony and wondering whether the recent excitement lines up with its underlying value, you are not alone. The stock closed at US$8.61 recently, with returns of 17.5% over 7 days, 9.8% over 30 days, 45.2% year to date and 367.9% over 1 year, while the 3 year return is very large and the 5 year return stands at 441.5%. These moves have put the company back on the radar for investors who track materials and specialty metals stocks, especially given its...

Pure Storage has recently drawn heightened attention as investors focus on its strong earnings outlook, profitability, recurring long-term contracts, and expanding free cash flow, while the company also updates its partner programs to emphasize solutions-led engagement and managed services. A distinctive aspect of these developments is the new Ambassador partner tier, which targets highly skilled partners and could deepen adoption of Pure Storage’s data platform across key solution areas...